NEW YORK, Feb. 10 (GenomeWeb News) - Serenex today said it has signed an evaluation agreement for its chemoproteomics technology with Aventis.

Aventis Pharmaceuticals, the Bridgewater, NJ-based subsidiary of Strasbourg, France-based Aventis, will "evaluate the utility" of Serenex's Proteome Mining and Functional Proteome Fractionation profiling technologies, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.